Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy dose escalation with PET-adapted chemotherapy in definitive chemoradiation for oesophageal cancer
2015-001740-11Phase 2Unknown
- Sponsor
- Velindre University NHS Trust
- Start
- Apr 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, cisplatin, carboplatin, paclitaxel and fluorouracil in esophageal cancer and esophagogastric junction cancer (3 arms), sponsored by Velindre University NHS Trust. Primary endpoint: Effectiveness of elevated-dose radiotherapy. Status: unknown.
02
Drugs
capecitabinecisplatincarboplatinpaclitaxelfluorouracil
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2015-001740-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001740-11.